July 11, 2008
Huvepharma makes foray into antibiotics market
press release
As some companies exit the medicated feed additive business, Huvepharma is going the opposite way as it targets to gain a strong position in the market.
Huvepharma sees the potential in the pharmaceutical business. With some major players stepping out, Huvepharma has seized the opportunity by purchasing two companies'' medicated feed additive arms, and may look to additional acquisitions in the future.
For years, Huvepharma has enjoyed good business in the enzyme and anticoccidial market but now the company aims to have a full range of veterinary medicine in three years'' time with its focus on livestock and poultry. However, the company currently has no plans to produce vaccines and biological substances.
Huvepharma believes that antibiotics are still required in livestock production despite ongoing controversy on the substance''s usage. The company has introduced its new line of products-- Pharmasin, Vetmulin and Tilmovet, all of which are available as water-soluble granules, medicated feed premixes, oral granules or injectables. Vetmulin and Tilmovet will also be available as a water-soluble solution. The products would be available for both pigs and poultry with Huvepharma intending to launch its own marketing campaign for these products.
In 2005, Huvepharma bought Intervet''s feed additives business. It also acquired certain anticoccidials and a formulation plant from Merial in 2007.
Headquartered in Sofia, Bulgaria, Huvepharma is a global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. The company also manufactures and markets enzymes for
food, feed and industrial applications.
Huvepharma has offices and subsidiaries in Bulgaria, Poland, China, Taiwan, Thailand, the US and Russia.